Journal: eLife

Article Title: Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α

doi: 10.7554/eLife.52668

Figure Lengend Snippet: Recombinant human G-CSF, GM-CSF, IL-4, IL-6, IL-10, IL-12, TNF-α, IL-1RA, MIP-1α, MIP-1β or RANTES were added either individually ( A and B ) or in combination pools ( C ) to Mtb-infected microspheres at ‘low’ concentrations, defined as that measured in media around spheres after anti-PD-1 treatment. Recombinant human TNF-α increases growth of Mtb, whilst other pro-inflammatory cytokines did not ( A ). GM-CSF has a lesser growth-promoting effect ( B ). The only combination pool that increased Mtb growth was the pro-inflammatory cytokine pool, containing TNF-α ( C ). ( D ) TNF-α results in a dose-dependent increase in the Mtb growth over time. ( E ) Anti-TNF-α neutralising antibodies partially suppress the increased Mtb growth caused by TNF-α augmentation. Anti-TNF-α from Thermo Fisher Scientific. ( F ) Anti-PD1 antibody incorporation within microspheres increases of Mtb growth at day 7, and this effect is reversed by concurrent anti-TNF-α neutralising antibodies within microspheres. The constituent of the cytokine pools are: Growth factor pool (GF: GM-CSF and G-CSF), Anti-Inflammatory cytokine pool (Anti-Inf: IL-10 and IL-1RA), Pro-Inflammatory cytokine pool (Pro-Inf: TNF-α, IL-6 and IL-12) and Chemokine pool (Chemo: RANTES, MIP-1α, MIP-1β).

Article Snippet: , Recombinant Human RANTES , ImmunoTools , Cat.No.11343196 , 0.3 ng/ml and 1.5 ng/ml.

Techniques: Recombinant, Infection

Journal: eLife

Article Title: Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α

doi: 10.7554/eLife.52668

Figure Lengend Snippet: Human recombinant G-CSF, GM-CSF, IL-4, IL-6, IL-10, IL-12, TNF-α, IL-1RA, MIP-1α, MIP-1β and RANTES were added to microspheres either individually or in combination pools to microspheres at five times the concentrations in , determined by the concentration measured in the media around the microspheres. TNF-α increases Mtb growth in microspheres alone and in the pro-inflammatory pool.

Article Snippet: , Recombinant Human RANTES , ImmunoTools , Cat.No.11343196 , 0.3 ng/ml and 1.5 ng/ml.

Techniques: Recombinant, Concentration Assay

Journal: eLife

Article Title: Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α

doi: 10.7554/eLife.52668

Figure Lengend Snippet:

Article Snippet: , Recombinant Human RANTES , ImmunoTools , Cat.No.11343196 , 0.3 ng/ml and 1.5 ng/ml.

Techniques: Infection, Control, Negative Control, Sequencing, Gene Expression, Cytotoxicity Assay, Activity Assay, Recombinant, Software

Journal: Scientific Reports

Article Title: Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis

doi: 10.1038/srep43718

Figure Lengend Snippet: ( a ) Representative pictures of migrated HUVECs (stained by crystal violet) treated with OPNs ± 20S proteasome are displayed. The quantitative effect of OPNs ± 20S proteasome (and VEGF-α as positive control) on the HUVEC chemotaxis (n = 6–38) is shown. ( b ) Representative pictures of migrated PBLs treated with OPNs ± 20S proteasome are displayed. The quantitative effect of OPNs ± 20S proteasome (and RANTES as positive control) on the chemotaxis of PBLs (n = 6–18) is shown. ( c ) Representative pictures of migrated PBMs treated with OPNs ± 20S proteasome are displayed. The quantitative effect of OPNs ± 20S proteasome (and RANTES as positive control) on the chemotaxis of PBMs (n = 11–13) is shown. In ( a–c ) cell migration is measured by applying the Boyden chamber migration assay; values are percentage of treated vs untreated cells that migrated after 20 h and are the mean and the SD of independent experiments. Wilcoxon test for paired samples p < 0.05 are shown.

Article Snippet: 10 μg/ml OPN-FL, OPN-C and OPN-N ( ) or 10–500 nM OPN-C peptides ( and ), are placed in the basolateral chamber; 10 ng/ml vascular endothelial growth factor-α (VEGF-α; Sigma-Aldrich) or 1 ng/ml recombinant human RANTES (rh RANTES/CCL5; ImmunoTools GmbH) are placed as reference chemoattractant for the HUVECs or the PBLs and the PBMs, respectively.

Techniques: Staining, Positive Control, Chemotaxis Assay, Migration

Journal: Scientific Reports

Article Title: Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis

doi: 10.1038/srep43718

Figure Lengend Snippet: The proteasome release by HUVECs (left panel) and PBLs (right panel) in serum-free medium with OPN-FL, OPN-N, OPN-C and VEGF-α (with HUVECs) or RANTES (with PBLs) is shown. Values are reported as proteasome concentration ratio of treated vs untreated cells and they correspond to the mean and the SD of independent experiments (HUVECs, n = 14; PBLs, n = 10) measured by ELISA. Statistically significant variations from the control are detected by Wilcoxon test for paired samples and p < 0.05 are annotated.

Article Snippet: 10 μg/ml OPN-FL, OPN-C and OPN-N ( ) or 10–500 nM OPN-C peptides ( and ), are placed in the basolateral chamber; 10 ng/ml vascular endothelial growth factor-α (VEGF-α; Sigma-Aldrich) or 1 ng/ml recombinant human RANTES (rh RANTES/CCL5; ImmunoTools GmbH) are placed as reference chemoattractant for the HUVECs or the PBLs and the PBMs, respectively.

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay, Control

Journal: Experimental Hematology & Oncology

Article Title: Depletion of polyfunctional CD26 high CD8 + T cells repertoire in chronic lymphocytic leukemia

doi: 10.1186/s40164-023-00375-5

Figure Lengend Snippet: CD26 + CD8 + T cells exhibit a greater migratory capacity in CLL. A Representative plots of the frequency of CCR5 + CD8 + T cells among CD26 neg/low/high subsets. B The graphical illustrates the tendency of CCR5 + CD8 + T cells homing to secondary lymphoid organs or inflamed tissues in response to CCL3, MIP-1 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\alpha$$\end{document} α / \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\beta$$\end{document} β , and RANTES. C Cumulative data of the frequency of CCR5 + CD8 + T cells among CD26 neg/low/high CD8 + T cells in CLL. D Representative flow plots of the frequency CCR6 + CD8 + T cells among CD26 neg/low/high subsets. E The graphical illustrates the tendency of CCR6 + CD8 + T cells homing to colon, and mucosal tissues in response to CCL20. F Cumulative data of the frequency of CCR6 + CD8 + T cells among CD26 neg/low/high . G Representative plots of the frequency of CCR7 + CD8 + T cells among CD26 neg/low/high subsets of CD8 + T cells. H The graphical illustrates the tendency of CCR7 + CD8 + T cells homing to lymph nodes in response to CCL19. I Cumulative data of the frequency of CCR7 + CD8 + T cells among CD26 neg/low/high subsets. J Representative plots of the frequency of Cutaneous Lymphocyte Antigen (CLA) + CD8 + T cells among CD26 neg/low/high cells. K The graphical illustrates the tendency of CLA + CD8 + T cells homing to skin following E/P Selectin binding on endothelial cells. L Cumulative data of the frequency of CLA + CD8 + T cells among CD26 neg/low/high cells. M Representative plots, and the frequency of migrated CD26 neg , CD26 low , and CD26 high CD8 + T cells at the baseline and after 18 h in response to ( N ) Fetal Bovine Serum (FBS-10%), ( O ) RANTES (10 nM), and ( P ) IL-18 (100 ng/ml). Error bars represent the median with an interquartile range. Each dot represents an individual human sample.

Article Snippet: The next day, FBS (10%), recombinant human RANTES (CCL5) (R and D, 10 nM), and recombinant human IL-18 (Biolegend, 100 ng/ml) were used as chemoattractants.

Techniques: Binding Assay